Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued reports about the stock. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Mizuho cut their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Finally, Barclays decreased their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Price Performance

NASDAQ:RVNC opened at $3.65 on Tuesday. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $6.65. The company has a 50-day moving average of $3.60 and a 200 day moving average of $4.31. The firm has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90.

Institutional Trading of Revance Therapeutics

Institutional investors have recently made changes to their positions in the business. Alpine Global Management LLC purchased a new stake in Revance Therapeutics in the fourth quarter valued at about $37,000. Two Sigma Investments LP increased its holdings in shares of Revance Therapeutics by 8.6% during the fourth quarter. Two Sigma Investments LP now owns 170,136 shares of the biopharmaceutical company’s stock valued at $517,000 after acquiring an additional 13,539 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of Revance Therapeutics by 19.3% during the fourth quarter. ProShare Advisors LLC now owns 75,252 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 12,155 shares in the last quarter. Man Group plc raised its position in shares of Revance Therapeutics by 47.8% in the 4th quarter. Man Group plc now owns 443,544 shares of the biopharmaceutical company’s stock valued at $1,348,000 after purchasing an additional 143,544 shares during the last quarter. Finally, Newtyn Management LLC acquired a new stake in Revance Therapeutics in the 4th quarter worth approximately $5,502,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.